Cost effectiveness of antidepressant treatment reassessed

British Journal of Psychiatry

Volumn 170, Issue MAR., 1997, Pages 257-263

  Woods, Scott W ^a,b   Rizzo, John A ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Yale University School of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMIPRAMINE; PAROXETINE; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT;

ARTICLE; COST EFFECTIVENESS ANALYSIS; DEPRESSION; DRUG COST; HUMAN;

EID: 0030890188     PISSN: 00071250     EISSN: None     Source Type: Journal    
DOI: 10.1192/bjp.170.3.257     Document Type: Article

References (19)

1. Agency for Health Care Policy and Research (1993) Depression in Primary Care, vol. 2. Treatment of Major Depression Rockville, MD: US Department of Health and Human Services.
2. Anderson, I. M. & Tomenson, B. M. (1995) Treatment discontinuation with selective serotonin reuptake inhibitors compared with tricyclic antidepressants: A meta-analysis. British Medical Journal, 310, 1433-1438.
3. Dunbar, G. C., Cohn, J. B., Fabre, L. F., et al (1991) A comparison of paroxetine, imipramine and placebo in depressed out-patients. British Journal of Psychiatry, 159, 394-398.
4. Dunner, D. L. & Dunbar, G. C. (1992) Optimal dose regimen for paroxetine. Journal of Clinical Psychiatry, 53, 21-26.
5. Freemantle, N., House, A., Song, F., et al (1994) Prescribing selective serotonin reuptake inhibitors as strategy for prevention of suicide. British Medical Journal, 309, 249-253.
6. _, _, Mason, J., et al (1995) Economics of treatment of depression (letter). British Journal of Psychiatry, 166, 397-399.
7. Jönsson, B. & Bebbington, P. (1993) Economic studies of the treatment of depressive illness. In Health Economics of Depression (eds B. Jönsson & J. Rosenbaum), pp. 35-48. Chichester: Wiley.
8. _ & _ (1994) What price depression? The cost of depression and the cost-effectiveness soft pharmacological treatment. British Journal of Psychiatry, 164, 665-673.
9. _ & _ (1995a) Reply to Freemantle et al (letter). British Journal of Psychiatry, 166, 398-399.
10. _ & _ (1995b) Reply to Owens (letter). British Journal of Psychiatry, 167, 112.
11. Katon, W., Von Korff, M., Lin, E., et al (1995) Collaborative management to achieve treatment guidelines. Impact on depression in primary care. Journal of the American Medical Association, 273, 1026-1031.
12. Montgomery, S. A., Henry, J., McDonald, G., et al (1994) Selective serotonin reuptake inhibitors: Meta-analysis of discontinuation rates. International Clinical Psychopharmacalogy, 9, 47-53 (erratum: 9, 296).
13. Nielsen, O. A., Morsing, I., Petersen, J. S., et al (1991) Paroxetine and imipramine treatment of depressive patients in a controlled multicentre study with plasma amino acid measurements. Acta Psychiatrica Scandinavica, 84, 233-241.
14. Ohrberg, S., Christiansen, P. E., Severin, B., et al (1992) Paroxetine and imipramine in the treatment of depressive patients in psychiatric practice. Acta Psychiatrica Scandinavica, 86, 437-444.
15. Owens, D. W. (1995) Economics of treatment of depression. British Journal of Psychiatry, 167, 112.
16. Paykel, E. S. & Priest, R. G. (1992) Recognition and management of depression in general practice: Consensus statement. British Medical Journal, 395, 1198-1202.
17. Simon, G. E., Vonkorff, M., Heiligenstein, J. H. et al (1996) Initial antidepressant choice in primary care. Effectiveness and cost of fluoxetine vs tricyclic antidepressants. Journal of the American Medical Association, 275, 1897-1902.
18. Thompson, C. (1995) Economics of treatment of depression. British Journal of Psychiatry, 167, 112.
19. Wells, K. B., Burnam, M. A. & Camp, P. (1995) Severity of depression in prepaid and fee-for-service general medical and mental health specialty practices. Medical Care, 33, 350-364.